Key result
Cilostazol significantly reduced mean left carotid intima-media thickness (-0.052 mm vs 0.023 mm) compared to other antiplatelets in patients with symptomatic ischemic stroke.
Why the study?
Does cilostazol reduce the progression of carotid IMT in symptomatic ischemic stroke patients?
Cohort (n=208)
Single-blind
No
Does cilostazol reduce the progression of carotid IMT in symptomatic ischemic stroke patients?
Absolute Event Rate: -0.052% vs 0.023%
p-value: p=<0.001
Cilostazol causes a significant regression in carotid IMT in symptomatic stroke patients compared to other antiplatelet therapies.
No takes yet. Share an insight, caveat, or question.
May slow carotid atherosclerosis progression in stroke; hypothesis-generating and should not yet change antiplatelet practice.
Heo et al. (2012) conducted a cohort in Symptomatic ischemic stroke or transient ischemic attack (n=208). Cilostazol vs. Antiplatelets other than cilostazol (aspirin, clopidogrel, or triflusal) was evaluated on Change in mean left common carotid artery intima-media thickness (CCA-IMT) in mm (p=<0.001). Cilostazol significantly reduced mean left carotid intima-media thickness (-0.052 mm vs 0.023 mm) compared to other antiplatelets in patients with symptomatic ischemic stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: